Cogent Biosciences
COGT
176 hedge funds and large institutions have $949M invested in Cogent Biosciences in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 63 increasing their positions, 46 reducing their positions, and 23 closing their positions.
65% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 23
37% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 46
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
9% more funds holding
Funds holding: 161 → 176 (+15)
1.12% less ownership
Funds ownership: 111.31% → 110.19% (-1.1%)
28% less capital invested
Capital invested by funds: $1.32B → $949M (-$367M)
60% less call options, than puts
Call options by funds: $1.54M | Put options by funds: $3.87M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.2M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$14.5M |
| 3 |
SG Americas Securities
New York
|
+$9.29M |
| 4 |
SCM
Superstring Capital Management
New York
|
+$9.08M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.84M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$51.1M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$21.6M |
| 3 |
Millennium Management
New York
|
-$15.5M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$14.4M |
| 5 |
DM
Deerfield Management
New York
|
-$11.1M |
COGT Hedge Fund Activity: Q4 2024 in Review
176 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q4 2024, worth a combined $949M — down 28% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new COGT positions and 23 closed out — a net gain of 15 holders — while 63 added to existing stakes and 46 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $82.2M. The largest seller was Point72 Asset Management, cutting an estimated $51.1M.
- 176 institutional investors held Cogent Biosciences (COGT) as of Q4 2024, up from 161 in Q3 2024.
- Funds reported $949M of Cogent Biosciences stock for Q4 2024, down 28% quarter-over-quarter.
- 38 funds opened new Cogent Biosciences positions in Q4 2024 and 23 closed out, a net change of +15 holders.
- The largest Cogent Biosciences buyer in Q4 2024 was Fidelity Investments, an estimated $82.2M added.
- The largest Cogent Biosciences seller in Q4 2024 was Point72 Asset Management, an estimated $51.1M sold.
Based on aggregated 13F filings for Q4 2024.